Please ensure Javascript is enabled for purposes of website accessibility

Why Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines Are Up by Double Digits Today

By Brian Feroldi - Updated Apr 14, 2019 at 11:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of all three cancer-focused companies shot higher after one of their peers got bought out for a sizable premium.

Check out the latest Array BioPharma and Blueprint Medicines earnings call transcripts.

What happened

Shares of Array BioPharma (ARRY)Deciphera Pharmaceuticals (DCPH 0.84%), and Blueprint Medicines (BPMC -1.15%) rose as much as 14%, 19%, and 16%, respectively, in early morning trading on Monday. All three companies' stocks settled down in the early afternoon but were still up at least 9% as of 3:30 p.m. EST. The price moves appear to be related to the news that fellow cancer-focused biopharma Loxo Oncology (LOXO) has agreed to be purchased by Eli Lilly and Company (LLY 0.15%)

Biotech stocks, in general, are having a great day. Shares of the SPDR S&P Biotech ETF (XBI 3.06%) were up more than 5% in the early afternoon. 

So what

News broke on Monday morning that Loxo Oncology had accepted an $8 billion buyout offer by Eli Lilly. The acquisition price translates into a 68% premium to Loxo's closing price on Friday, Jan. 4.

Lilly said that it agreed to offer such a huge premium to acquire Loxo because it wants to broaden its portfolio of oncology products to be used in the growing field of precision medicine. Buying Loxo was a natural fit as the company recently won approval for its first cancer drug, Vitrakvi, a TRK inhibitor that targets tumors with specific genetic abnormalities.

Doctor giving double thumbs-up

Image source: Getty Images.

Traders appear to believe that this sizable financial move by Lilly could convince other big pharma companies to go on a shopping spree. If that happens, it could be great news for investors in Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines since all of these businesses are developing precision-medicine oncology products of their own.

Array BioPharma has already reached the market with two cancer drugs, Braftovi and Mektovi. Sales for these drugs recently came in at $14 million last quarter, which is pretty good when considering that they only became available for sale in July 2018.

Deciphera Pharmaceuticals is still in the clinical stage, but its lead drug candidate, DCC-2618, holds a lot of promise. Deciphera released upbeat data in 2018 from a phase 1 trial of the drug as a potential treatment for gastrointestinal stromal tumors (GIST) with a specific genetic mutation. The results were so good that the company decided to move straight into a phase 3 trial.

Blueprint Medicines is another clinical-stage company whose stock has been red-hot for years. Blueprint has a number of products in development as potential treatments for specific types of liver cancer. Management recently announced that it has set a goal of having two of its products on the market by the end of 2020, and at least four other products in regulators' hands by the same time. That time frame suggests that the next few years will be an incredibly exciting period for investors. 

Now what

Healthcare investors should expect that the next couple of days will be a highly volatile stretch for scores of individual stocks. The reason is that the annual J.P. Morgan Healthcare Conference is just getting underway. It's common for companies to give presentations at the conference in which they share market-moving information such as clinical or financial updates. 

Array BioPharma and Blueprint Medicines both gave their investor presentations earlier in the day. Deciphera Pharmaceuticals is scheduled to provide investors with a detailed update on Tuesday.

If you're an investor in any of these businesses, then it will be worth your while to comb through their presentations to get the latest information.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Array Technologies, Inc. Stock Quote
Array Technologies, Inc.
ARRY
Blueprint Medicines Stock Quote
Blueprint Medicines
BPMC
$49.93 (-1.15%) $0.58
Deciphera Pharmaceuticals, Inc. Stock Quote
Deciphera Pharmaceuticals, Inc.
DCPH
$13.26 (0.84%) $0.11
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$324.71 (0.15%) $0.48
SPDR Series Trust - SPDR S&P Biotech ETF Stock Quote
SPDR Series Trust - SPDR S&P Biotech ETF
XBI
$76.54 (3.06%) $2.27
Loxo Oncology Stock Quote
Loxo Oncology
LOXO

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.